J. Morden

发表

Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study

K. Abrams, P. Lambert, A. Wailoo, 2011, BMC medical research methodology.

Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial

Emma Hall, Kevin J Harrington, S. Bhide, 2011, The Lancet. Oncology.

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial

R. Laing, P. Ellis, H. Earl, 2017, The Lancet. Oncology.

Long-Term Follow-Up of the Intergroup Exemestane Study.

P. Lønning, L. Fallowfield, R. Paridaens, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P. Lønning, J. Forbes, R. Paridaens, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation

Christopher A. Miller, E. Mardis, M. Dowsett, 2016, Nature Communications.

Current attitudes of head and neck oncologists in the United Kingdom to induction chemotherapy for locally advanced head and neck cancer: a survey of centres participating in a national randomised controlled trial.

S. Bhide, K. Harrington, C. Nutting, 2014, Oral oncology.

Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative orBRCA1/2breast cancer (CRUK/07/012)

N. Rahman, M. Dowsett, P. Ellis, 2015 .

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial

J. Yarnold, C. Coles, N. Somaiah, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Genomic Instability and TP53 Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment

M. Dowsett, M. Cheang, J. Robertson, 2019, JCO precision oncology.

Adjusting survival time estimates to account for treatment switching in randomised controlled trials – a simulation study

R. Akehurst, K. Abrams, P. Lambert, 2013 .

Immunogenicity of pandemic (H1N1) 2009 vaccine in children with cancer in the United Kingdom.

K. Hoschler, J. Bate, J. Morden, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.

C. V. D. van de Velde, R. C. Coombes, J. Bliss, 2012, The Lancet. Oncology.

DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer

S. Bhide, K. Harrington, T. Roques, 2016, BMC Cancer.

Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial

R. Eeles, H. Kitchener, M. Gore, 2016 .

Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial.

S. Bhide, K. Harrington, T. Roques, 2021, European journal of cancer.

Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial

I. Judson, B. Seddon, M. Tattersall, 2019, The Lancet. Oncology.

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

Bingshu E. Chen, D. Berry, P. Fasching, 2019, The Lancet.

Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy

S. Bhide, K. Harrington, C. Nutting, 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer

M. Koehler, Xin Huang, M. Cristofanilli, 2018, Nature Communications.

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer

M. Koehler, Xin Huang, M. Cristofanilli, 2018, Nature Communications.

Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial

M. Dowsett, M. Cheang, E. Mallon, 2020, The Lancet. Oncology.

Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas

M. Dowsett, J. Parker, M. Cheang, 2016, Breast Cancer Research.

Fatigue during chemoradiotherapy for nasopharyngeal cancer and its relationship to radiation dose distribution in the brain.

S. Bhide, K. Harrington, C. Nutting, 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients

M. Dowsett, M. Cheang, E. Mallon, 2019, Breast Cancer Research.

Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer

H. Putter, P. Kuppen, C. V. D. van de Velde, 2018, Breast Cancer Research and Treatment.

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

M. Dowsett, T. Julian, M. Cheang, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study

Keith R Abrams, Michael J Crowther, Nicholas R Latimer, 2018, Statistical methods in medical research.

Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial.

R. Eeles, H. Kitchener, M. Gore, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dosimetric explanations of fatigue in head and neck radiotherapy: an analysis from the PARSPORT Phase III trial.

K. Harrington, C. Clark, M. Partridge, 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Adjusting Survival Time Estimates to Account for Treatment Switching in Randomized Controlled Trials—an Economic Evaluation Context

Keith R Abrams, Michael J Crowther, Nicholas R Latimer, 2014, Medical decision making : an international journal of the Society for Medical Decision Making.

Abstract GS1-03: Peri-operative aromatase inhibitor treatment in determining or predicting longterm outcome in early breast cancer – The POETIC* Trial (CRUK/07/015)

M. Dowsett, J. Robertson, E. Mallon, 2018 .

Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results

E. Rakha, D. Cameron, D. Dodwell, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)

M. Dowsett, L. Zabaglo, E. Mallon, 2023, Breast Cancer Research.

First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015).

Joanne S Haviland, John R Yarnold, J. Yarnold, 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004)

S. Bhide, K. Harrington, C. Nutting, 2018, European journal of cancer.

Activity of cediranib in alveolar soft part sarcoma (ASPS) confirmed by CASPS (cediranib in ASPS), an international, randomised phase II trial (C2130/A12118).

I. Judson, B. Seddon, J. Bliss, 2017 .

Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor–Positive Breast Cancer

M. Dowsett, E. Mallon, I. Smith, 2018, JNCI cancer spectrum.

Abstract OT1-06-03: The plasmaMATCH trial: A multiple parallel cohort, open-label, multi-centre phase II clinical trial of ctDNA screening to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010)

A. Wardley, R. Roylance, N. Turner, 2018 .

Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.

S. Bhide, K. Harrington, C. Clark, 2011, The Lancet. Oncology.

NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer

Sung-Bae Kim, M. Cheang, R. Coombes, 2014, Breast Cancer Research and Treatment.